Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64,521,093
-
Total 13F shares
-
57,917
-
Share change
-
+15,103
-
Total reported value
-
$246,727
-
Price per share
-
$4.26
-
Number of holders
-
2
-
Value change
-
+$64,339
-
Number of buys
-
2
Institutional Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q4 2023
As of 31 Dec 2023,
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,917 shares.
The largest 10 holders included
ADAGE CAPITAL PARTNERS GP, L.L.C., Pivotal bioVenture Partners Investment Advisor LLC, Sofinnova Investments, Inc., Rock Springs Capital Management LP, SAMLYN CAPITAL, LLC, EVENTIDE ASSET MANAGEMENT, LLC, BlackRock Inc., NEA Management Company, LLC, VANGUARD GROUP INC, and FMR LLC.
This page lists
80
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.